On September 8, 2021 Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, reported that results from validation studies demonstrating the reliable performance of the StrataNGS test were published in The Journal of Molecular Diagnostics (Press release, Strata Oncology, SEP 8, 2021, View Source [SID1234587442]). StrataNGS is a 429-gene, multiplex PCR-based comprehensive genomic profiling (CGP) test performed on co-isolated DNA and RNA from formalin-fixed paraffin-embedded (FFPE) tissue tumor specimens with >2mm2 tumor surface area.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Through a unique assay configuration and novel bioinformatics pipeline optimized for multiplex PCR-based sequencing, StrataNGS demonstrated high sensitivity and specificity for detecting single nucleotide variants, insertions/deletions, gene fusions, copy number alterations, microsatellite instability and tumor mutation burden. Designed to provide comprehensive assessment of clinically actionable biomarkers from minute FFPE solid tumor tissue samples, StrataNGS substantially increases patient access to tissue-based CGP. A recent study of >30,000 real-world tumor tissue samples received for CGP found that only 41.6% of samples met minimum tissue requirements (>25mm2 tumor surface area) for several leading hybrid capture-based CGP tests.
"StrataNGS demonstrated the sensitivity and specificity required for routine clinical practice while reporting all CGP variant classes from minute FFPE tissue samples," said Scott Tomlins, M.D., Ph.D., co-founder and Chief Medical Officer, Strata Oncology. "Conventional tissue-based CGP and liquid biopsy tests often fail to meet either the sensitivity or success rate needed to deliver reliable results for each patient. StrataNGS nearly eliminates the insufficient tissue problem, while delivering the sensitivity required to confidently rule-in or out a treatment. This approach directly translates into treatment insights for more patients."
About StrataNGS
StrataNGS is a comprehensive genomic profiling (CGP) test that features the lowest tumor tissue requirements in the industry (≥2mm2 surface area). The 429-gene assay is performed on co-isolated RNA and DNA. Single-/multi-nucleotide variants (SNVs), short insertions and deletions (indels), copy number alterations (CNAs; amplifications and deep deletions), microsatellite instability (MSI) status, gene fusions, and tumor mutation burden (TMB) are assessed simultaneously.